COMMUNIQUÉS West-GlobeNewswire

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
29/06/2026
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and [...]
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité
29/06/2026
Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité L’obéfazimod a apporté [...]
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
29/06/2026
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database [...]
Dragon Pharma Store Announces Expansion of Research Product Catalog with Addition of KLOW 80mg
29/06/2026
New York, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Dragon Pharma Store announced the addition of KLOW 80mg to its online research product catalog, reflecting continued expansion of available laboratory research materials [...]
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
29/06/2026
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free [...]
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
29/06/2026
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA., June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a [...]
Publication relative à des notifications de transparence
29/06/2026
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 29 juin 2026 , 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Publication relating to transparency notifications
29/06/2026
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 29, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the [...]
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
29/06/2026
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision [...]
Tilray Brands Strengthens Global Medical Cannabis Platform and Canadian Patient Access Through HelloMD Acquisition
29/06/2026
Acquisition Will Expand Patient Access, Strengthen Digital Healthcare Capabilities, and Create a Fully Vertically Integrated Medical Cannabis Framework for Tilray in Canada NEW YORK and TORONTO, June 29, 2026 (GLOBE [...]
Zoumalan, MD FACS Inc. Announces Its Natural Looking Blepharoplasty® Approach as Demand Grows for Natural Eyelid Surgery Results
29/06/2026
Board-certified ophthalmologist and ASOPRS fellowship-trained surgeon Dr. Christopher I. Zoumalan, MD, FACS, explains how his trademarked Natural Looking Blepharoplasty® reflects the 2026 “less-is-more” movement in [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2026
29/06/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
BrewDog and Tilray Beer Add Canada to The World's Biggest Bar Tab as Canada Advances to the Next Round
29/06/2026
Canada, England or the U.S. to the final? BrewDog and Tilray Beer are ready to pour a £1 million bar tab for fans across participating BrewDog pubs 1 and Tilray-owned brewpubs 2 . NEW YORK and TORONTO and ELLON, United [...]
EmblemHealth Sees 50% Increase in Member Adoption and Engagement Following Debut of Redesigned Mobile App
29/06/2026
Early adoption data shows strong usage of in-app digital health management tools, including personalized health journeys, health assessments, and social needs screenings. NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- [...]
Résultats AGE - 29 juin 2026
29/06/2026
Résultats des votes AGE du 29 juin 2026 Pièce jointe Résultats AGE 29-06-2026 - IBA SA
EssilorLuxottica: Déclaration de transactions sur actions propres
29/06/2026
Déclaration de transactions sur actions propres Paris, France (29 juin 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 28 avril 2026, EssilorLuxottica déclare que du 24 juin 2026 au 25 [...]
EssilorLuxottica: Disclosure of transactions in own shares
29/06/2026
Disclosure of transactions in own shares Paris, France (June 29, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 28, 2026, EssilorLuxottica declares that from [...]
Father and son climb Kilimanjaro for Human Appeal’s humanitarian work
29/06/2026
MANCHESTER, United Kingdom, June 29, 2026 (GLOBE NEWSWIRE) -- Human Appeal’s Global Director of Fundraising, Zaheer Khan, will travel to Tanzania this summer to climb Mount Kilimanjaro alongside his 16-year-old son, in [...]
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
29/06/2026
Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025. [...]

Pages